1.GTP cyclohydrolase 1 gene 3'-UTR C+243T variant predicts worsening outcome in patients with first-onset ischemic stroke.
Ling TANG ; Lan ZHANG ; Hu DING ; Wei TU ; Jiangtao YAN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2010;30(6):694-698
Tetrahydrobiopterin (BH4) is an essential cofactor for all three nitric oxide synthase (NOS isoforms), which plays an important role in vascular diseases. GTP cyclohydrolase 1 (GCH 1) is the first-step and rate-limiting enzyme for BH4 biosynthesis in its de novo pathway. Common GCH1 gene variant C+243T in the 3'-untranslated region predicts NO excretion. The present study examined the predictive role of GCH 1 gene 3'-UTR C+243T variant in the long-term outcome of ischemic stroke. A total of 142 patients with first-onset ischemic stroke were recruited and detected for genotype of GCH1 3'-UTR C+243T by a TaqMan SNP Genotyping assay. Subsequent vascular events and death were determined over a 5-year follow-up period. The frequency of GCH1 3'-UTR +243 C/T or T/T genotype was significantly increased in patients with endpoint events as compared with those without events (74% vs 57.8%, P=0.06). Cox regression survival analysis indicated that an increased probability of death or new vascular events was found in patients with GCH1 3'-UTR +243 C/T or T/T genotype compared with those with GCH1 3'-UTR C/C genotype (40.6% vs 25.5%), GCH1 3'-UTR +243 C/T or T/T genotype relative to GCH1 3'-UTR C/C genotype was associated with the increased risk of death or vascular events even after adjustment for other risk factors (OR=2.171, 95% CI: 1.066-4.424, P=0.033). It was concluded that GCH1 3'-UTR C+243T variant was an independent predictor of worsening long-term outcomes in patients with first-onset ischemic stroke.
3' Untranslated Regions
;
genetics
;
Aged
;
Brain Ischemia
;
genetics
;
Female
;
GTP Cyclohydrolase
;
genetics
;
Humans
;
Male
;
Middle Aged
;
Nitric Oxide
;
metabolism
;
Prognosis
;
Risk Factors
;
Stroke
;
diagnosis
;
genetics
2.A novel mutation in GCH1 gene causes dopa-responsive dystonia.
Weiqing WU ; Chunxi HAN ; Ying HAO ; Jiansheng XIE ; Zhiyong XU ; Qian GENG
Chinese Journal of Medical Genetics 2014;31(4):420-423
OBJECTIVETo identify potential mutation of the GCH1 gene in a Chinese family affected with dopa-responsive dystonia.
METHODSGenomic DNA of patients was extracted from peripheral blood samples. The 6 exons of the GCH1 gene and at least 100 bp of flanking intronic sequences were amplified with PCR. Potential mutations were screened by direct sequencing. Identified mutation was verified with denaturing high performance liquid chromatography (DHPLC) in 100 healthy controls.
RESULTSAll patients were found to be heterozygous for a novel c.597delT (p.Ala200LeufsX5) deletion in the exon 5 of the GCH1 gene. The deletion of T has resulted in formation of a shorter (203 amino acids) truncated non-functional guanosine triphosphate cyclohydrolase I. The same mutation was not found in the 100 controls.
CONCLUSIONA novel GCH1 gene frameshifing mutation probably underlies the dopa-responsive dystonia in this Chinese family.
Adolescent ; Adult ; Base Sequence ; Child ; Dystonic Disorders ; enzymology ; genetics ; Exons ; Female ; Frameshift Mutation ; GTP Cyclohydrolase ; genetics ; Humans ; Male ; Middle Aged ; Molecular Sequence Data ; Pedigree ; Young Adult
3.Dopa-responsive Dystonia with a Novel Initiation Codon Mutation in the GCH1 Gene Misdiagnosed as Cerebral Palsy.
Jae Hyeok LEE ; Chang Seok KI ; Dae Seong KIM ; Jae Wook CHO ; Kyung Phil PARK ; Seonhye KIM
Journal of Korean Medical Science 2011;26(9):1244-1246
Dopa-responsive dystonia (DRD) is a clinical syndrome characterized by childhood-onset dystonia and a dramatic response to relatively low doses of levodopa. However, patients with DRD can be misdiagnosed as cerebral palsy or spastic diplegia due to phenotypic variation. Here we report a young woman with DRD who were severely disabled and misdiagnosed as cerebral palsy for over 10 yr. A small dose of levodopa restored wheelchair-bound state to normality. However, thoracolumbar scoliosis has remained as a sequel due to late detection of DRD. Genetic analysis by using PCR-direct sequencing revealed a novel initiation codon mutation (c.1A>T; p.Met1Leu) in GTP cyclohydrolase 1 (GCH1) gene. Although it is known that DRD can be misdiagnosed as cerebral palsy, this case reinforces the importance of differential diagnosis of DRD from cerebral palsy.
Adult
;
Cerebral Palsy/diagnosis
;
Codon, Initiator
;
Diagnosis, Differential
;
Dystonic Disorders/*diagnosis/drug therapy/*genetics
;
Female
;
GTP Cyclohydrolase/*genetics
;
Humans
;
Levodopa/therapeutic use
;
Mutation
;
Sequence Analysis, DNA
4.Mutation analysis of GCH1 gene in Chinese patients with dopa responsive dystonia.
Jing LI ; Bei-sha TANG ; Ji-feng GUO ; Yu-hu ZHANG ; Zhi-guo XIE ; Xin-xiang YAN ; Lu SHEN ; Hong JIANG ; Xue-wei ZHANG ; Kun XIA ; Qian PAN
Chinese Journal of Medical Genetics 2007;24(3):302-304
OBJECTIVETo detect mutations of guanosine triphosphate cyclohydrolase I (GCH1) gene in Chinese patients with dopa responsive dystonia (DRD).
METHODSSix sporadic patients with DRD were examined. GCH1 gene mutations were detected using polymerase chain reaction (PCR), DNA sequence analysis and restriction enzyme digestion analysis. One hundred normal people were detected using PCR and restriction enzyme digestion analysis.
RESULTSA new point mutation, 151(G-->A) in exon one was found in a patient. It lead to substitution of a methionine for isoleucine at amino acid 1(M1I). This mutation was not found in normal control people.
CONCLUSIONThe authors report a new heterozygotic point mutation 151(G-->A) in GCH1 gene. There are GCH1 gene mutations in Chinese sporadic patients with DRD.
Asian Continental Ancestry Group ; genetics ; Case-Control Studies ; DNA ; genetics ; DNA Mutational Analysis ; Dihydroxyphenylalanine ; therapeutic use ; Dystonia ; drug therapy ; genetics ; Exons ; genetics ; Female ; GTP Cyclohydrolase ; genetics ; Humans ; Male ; Point Mutation ; genetics ; Polymerase Chain Reaction
5.Screening for tetrahydrobiopterin metabolic disorders and related gene analysis among the patients with motor disturbance and mental retardation.
Jun YE ; Xiao-qing LIU ; Wen-juan QIU ; Lian-shu HAN ; Jian-de ZHOU ; Ya-fen ZHANG ; Xue-fan GU
Chinese Journal of Medical Genetics 2007;24(2):210-212
OBJECTIVETo study the incidence of various enzyme deficiency in tetrahydrobiopterin (BH4) metabolism and the related gene mutation among the patients with motor disturbance and mental retardation.
METHODSOne hundred patients with unknown motor disturbance and mental retardation were referred to this study. All patients were performed by phenylalanine (Phe) and BH4 loading test, urinary pterin analysis and dihydropteridine reductase (DHPR) activity. Some patients received the dopa treatment for diagnosis of dopa-responsive dystonia (DRD). The analysis of GTP cyclohydrolase 1 gene (GCH1) mutation for DRD patients and the analysis of 6-pyruvoyl tetrahydropterin synthase (PTS) gene mutations for PTS deficient patients were done under the consent from their parents.
RESULTSSeventy of 100 patients had normal basic blood Phe levels, six (6%) patients were diagnosed as DRD. Thirty patients had hyperphenylalaninemia (HPA), eight (8%) were diagnosed as PTS deficiency and 22(22%) were diagnosed as phenylalanine hydroxylase (PAH) deficiency. All patients had normal DHPR activity. The mutation IVS5+3insT of GCH1 was found in 2 patients with DRD. Seven kinds of PTS mutations were found in 8 patients with PTS deficiency, and 75% of the mutations were 259C-->T,286G-->A and 155A-->G.
CONCLUSIONSome patients with unknown motor disturbance and mental retardation may suffer from BH4 metabolism related diseases. Theses patients are necessary to be screened for such kind of diseases in order to confirm the diagnosis.
Adolescent ; Biopterin ; analogs & derivatives ; metabolism ; Child ; Child, Preschool ; Dihydropteridine Reductase ; genetics ; metabolism ; Dystonia ; genetics ; metabolism ; Female ; GTP Cyclohydrolase ; genetics ; metabolism ; Humans ; Infant ; Intellectual Disability ; genetics ; metabolism ; Male ; Mutation ; Phenylalanine Hydroxylase ; genetics ; metabolism ; Phosphorus-Oxygen Lyases ; genetics ; metabolism
6.Predisposition of genetic disease by modestly decreased expression of GCH1 mutant allele.
Yo Sik KIM ; Yong Bock CHOI ; Jeong Hwa LEE ; Sei Hoon YANG ; Ji Hyun CHO ; Chang Ho SHIN ; Sang Do LEE ; Moon Kee PAIK ; Kyeong Man HONG
Experimental & Molecular Medicine 2008;40(3):271-275
Recently it was shown that single nucleotide polymorphisms (SNPs) can explain individual variation because of the small changes of the gene expression level and that the 50% decreased expression of an allele might even lead to predisposition to cancer. In this study, we found that a decreased expression of an allele might cause predisposition to genetic disease. Dopa responsive dystonia (DRD) is a dominant disease caused by mutations in GCH1 gene. The sequence analysis of the GCH1 in a patient with typical DRD symptoms revealed two novel missense mutations instead of a single dominant mutation. Family members with either of the mutations did not have any symptoms of DRD. The expression level of a R198W mutant allele decreased to about 50%, suggesting that modestly decreased expression caused by an SNP should lead to predisposition of a genetic disease in susceptible individuals.
Child
;
Clubfoot/genetics
;
Dopamine/deficiency
;
Dystonic Disorders/drug therapy/enzymology/*genetics/physiopathology
;
GTP Cyclohydrolase/*genetics/metabolism
;
Genes, Recessive
;
*Genetic Predisposition to Disease
;
Humans
;
Levodopa/administration & dosage
;
Male
;
Mutation, Missense
;
Pedigree
;
Polymorphism, Genetic
7.Combining Human and Rodent Genetics to Identify New Analgesics.
Alban LATREMOLIERE ; Michael COSTIGAN
Neuroscience Bulletin 2018;34(1):143-155
Most attempts at rational development of new analgesics have failed, in part because chronic pain involves multiple processes that remain poorly understood. To improve translational success, one strategy is to select novel targets for which there is proof of clinical relevance, either genetically through heritable traits, or pharmacologically. Such an approach by definition yields targets with high clinical validity. The biology of these targets can be elucidated in animal models before returning to the patients with a refined therapeutic. For optimal treatment, having biomarkers of drug action available is also a plus. Here we describe a case study in rational drug design: the use of controlled inhibition of peripheral tetrahydrobiopterin (BH4) synthesis to reduce abnormal chronic pain states without altering nociceptive-protective pain. Initially identified in a population of patients with low back pain, the association between BH4 production and chronic pain has been confirmed in more than 12 independent cohorts, through a common haplotype (present in 25% of Caucasians) of the rate-limiting enzyme for BH4 synthesis, GTP cyclohydrolase 1 (GCH1). Genetic tools in mice have demonstrated that both injured sensory neurons and activated macrophages engage increased BH4 synthesis to cause chronic pain. GCH1 is an obligate enzyme for de novo BH4 production. Therefore, inhibiting GCH1 activity eliminates all BH4 production, affecting the synthesis of multiple neurotransmitters and signaling molecules and interfering with physiological function. In contrast, targeting the last enzyme of the BH4 synthesis pathway, sepiapterin reductase (SPR), allows reduction of pathological BH4 production without completely blocking physiological BH4 synthesis. Systemic SPR inhibition in mice has not revealed any safety concerns to date, and available genetic and pharmacologic data suggest similar responses in humans. Finally, because it is present in vivo only when SPR is inhibited, sepiapterin serves as a reliable biomarker of target engagement, allowing potential quantification of drug efficacy. The emerging development of therapeutics that target BH4 synthesis to treat chronic pain illustrates the power of combining human and mouse genetics: human genetic studies for clinical selection of relevant targets, coupled with causality studies in mice, allowing the rational engineering of new analgesics.
Analgesics
;
therapeutic use
;
Animals
;
Biopterin
;
analogs & derivatives
;
metabolism
;
Chronic Pain
;
drug therapy
;
genetics
;
Disease Models, Animal
;
Drug Discovery
;
GTP Cyclohydrolase
;
genetics
;
metabolism
;
Humans
;
Rodentia
;
Signal Transduction
;
drug effects
;
genetics
8.Analysis of clinical phenotype and CGH1 gene mutations in a family affected with dopa-responsive dystonia.
Yaping YAN ; Xiaohong CHEN ; Wei LUO
Chinese Journal of Medical Genetics 2017;34(2):205-208
OBJECTIVETo explore genetic mutations and clinical features of a pedigree affected with dopa-responsive dystonia.
METHODSPCR and Sanger sequencing were applied to detect mutations of the GCH1 gene among 7 members from the pedigree.
RESULTSThe family was detected to have a known heterozygous mutation of the GCH1 gene (c.550C>T). For the 7 members from the pedigree, the age of onset has ranged from 13 to 60 years. The mother of the proband has carried the same mutation but was still healthy at 80. The symptoms of the other three patients were in slow progression, with diurnal fluctuation which can be improved with sleeping, dystonias of lower limbs, and tremor of both hands. Treatment with small dose of levodopa has resulted in significant improvement of clinical symptoms. By database analysis, the c.550C>T mutation was predicted as probably pathological.
CONCLUSIONThe c.550C>T mutation probably underlies the disease in this pedigree. The clinical phenotypes of family members may be variable for their ages of onset. Some may even be symptom free.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Base Sequence ; DNA Mutational Analysis ; Dystonic Disorders ; enzymology ; genetics ; Female ; GTP Cyclohydrolase ; genetics ; Heterozygote ; Humans ; Male ; Middle Aged ; Molecular Sequence Data ; Mutation ; Pedigree ; Phenotype ; Young Adult
9.Clinical analysis of dopa-responsive dystonia and mutation analysis of the GCH I gene.
Hui XIE ; Zhi-ying WU ; Ning WANG ; Zhi-wen LI ; Min-ting LIN ; Shen-xing MURONG
Chinese Journal of Pediatrics 2006;44(7):492-495
OBJECTIVETo investigate the clinical characteristics and GCH I gene mutations in patients with dopa-responsive dystonia (DRD).
METHODSThe clinical features of 3 families with 6 affected members and 8 sporadic cases were analyzed to determine the clinical characteristics, and 2 families with 4 affected members and 2 sporadic cases were screened for mutations of the GCH I gene.
RESULTSAge at onset was (10 +/- 3) years. Onset occurred earlier in female (9 +/- 4) years than in male (12 +/- 1) years. The initial symptom was a gait disorder, dystonia or tremor in most patients and nine patients (64%) presented with diurnal fluctuation. Thirteen patients (93%) were cured and one was improved after administration of low doses of levodopa for 3 months and no long-term side effects of levodopa had occurred. Two independent mutations were found in three patients. Gln161Pro, a new missense mutation, was found in a sporadic case, leading to a relatively severe phenotype. The two patients with mild phenotype in one family were found to have Lys224Arg mutation, as previously described.
CONCLUSIONSDRD patients have diverse phenotypes and diurnal fluctuation is an important feature. They have dramatic and sustained response to levodopa. There may be a correlation between genotype and phenotype. The detection of GCH I mutations is helpful in early diagnosis of non-typical cases.
Age of Onset ; Child ; China ; DNA Mutational Analysis ; Dopamine Agents ; therapeutic use ; Dystonia ; diagnosis ; drug therapy ; genetics ; physiopathology ; Early Diagnosis ; Female ; GTP Cyclohydrolase ; genetics ; Genotype ; Humans ; Levodopa ; therapeutic use ; Male ; Molecular Sequence Data ; Mutation ; Mutation, Missense ; Pedigree ; Phenotype ; Polymerase Chain Reaction ; Sex Factors ; Treatment Outcome
10.The mechanisms of extracellular-signal regulated protein kinase pathway in biopterin induction in rats with endotoxic shock.
Cai-lin XU ; Yong-ming YAO ; Feng-hua YAO ; Yan YU ; Zhi-yong SHENG
Chinese Journal of Surgery 2005;43(17):1127-1131
OBJECTIVETo observe the influence of treatment with the inhibitor of extracellular-signal regulated protein kinase (ERK) signal transduction pathway on the expression of biopterin/nitric oxide (NO) as well as the activation of nuclear factor-kappaB (NF-kappaB), and to clarify the potential cross-talk regulation mechanisms between ERK and NF-kappaB pathway in biopterin-mediated NO induction in rats with endotoxic shock.
METHODSUsing an endotoxic shock model, 60 male Wistar rats were randomly divided into normal controls (n = 8), endotoxic shock group (n = 32) and PD98059 treatment group (n = 20). At serial time points animals in each group were sacrificed, and tissue samples from liver, lungs as well as kidneys were harvested to detect NF-kappaB activity, guanosine triphosphate-cyclohydrolase (GTP-CHI) and inducible nitric oxide synthase (iNOS) mRNA expression. Biopterin and NO levels in plasma and tissues were also assayed.
RESULTSIt was found that after lipopolysaccharide (LPS) challenge, GTP-CHI mRNA expression and biopterin levels significantly elevated in liver, lungs and kidneys, keeping at high values up to 24 h, so did the values of iNOS mRNA expression and NO levels. NF-kappaB DNA binding activity was enhanced rapidly in various tissues, peaking at 2 h after LPS challenge. Treatment with PD98059, an inhibitor of ERK signal transduction pathway, could significantly inhibit GTP-CHI mRNA expression in kidneys, and GTP-CHI mRNA expression in liver and lungs showed certain down-regulation tendency. At the same time, biopterin level was significantly decreased in plasma, liver and kidneys at 12 h. Similarly, iNOS/NO induction at early stage markedly decreased in various tissues. In addition, treatment with PD98059 reduced NF-kappaB DNA binding activity in liver, lungs, as well as kidneys at 2-6 h, 2 h, 24 h and 24 h after LPS challenge, respectively.
CONCLUSIONSInhibition of ERK pathway could partially inhibit the production of biopterin/NO as well as the activation of NF-kappaB pathway, which indicated that cross-talk regulation seems to be existed between ERK and NF-kappaB pathway, and they might be involved in the regulatory process of biopterin-mediated nitric oxide induction in rats with endotoxic shock.
Animals ; Biopterin ; metabolism ; physiology ; Disease Models, Animal ; Extracellular Signal-Regulated MAP Kinases ; physiology ; GTP Cyclohydrolase ; biosynthesis ; genetics ; Male ; NF-kappa B ; metabolism ; Nitric Oxide ; biosynthesis ; Nitric Oxide Synthase Type II ; biosynthesis ; genetics ; Random Allocation ; Rats ; Rats, Wistar ; Shock, Septic ; physiopathology ; Signal Transduction